Peptide Encyclopedia / Livagen
EncyclopediaLivagen is a short synthetic peptide from the Khavinson bioregulator family, marketed as a liver-targeted agent with a proposed but unproven effect on gene expression. Its evidence rests on a weak base of Russian preclinical work, with no FDA approval. Below you'll find reported dosing, reconstitution, safety, and legal status. Educational only, not medical advice.
| Category | Longevity / Anti-aging |
| Regulatory status | Not FDA-approved; research chemical / gray-market in the US. |
A short synthetic peptide (commonly cited as the tetrapeptide Lys-Glu-Asp-Ala) from the Khavinson bioregulator family, marketed as a liver-targeted agent. Proposed (unproven) mechanism includes tissue-specific modulation of gene expression and chromatin decondensation in liver/lymphocyte cells.
uncertain / limited human pharmacokinetic data; presumed rapid clearance but no rigorous human PK exists.
Not FDA-approved; research chemical / gray-market in the US. Not an FDA-approved drug; sold within Russia in the bioregulator/supplement context only.
Human safety data are minimal and largely Russian-sourced. Rapid clearance suggests low acute risk but is not a substitute for controlled safety data. Gray-market purity/identity unverified.
Weak/limited evidence base: predominantly Russian (Khavinson group) preclinical work, with essentially no independent Western human replication.
PepWise is an informational and educational tracking tool, not medical advice and not a medical device. Livagen may be experimental, restricted, or prescription-only; many research peptides are not FDA-approved. Consult a licensed healthcare provider before starting, changing, or stopping any protocol. Operated by STC Consulting, Inc.
